SG160342A1 - Inhibition or treatment of dyskinesia - Google Patents
Inhibition or treatment of dyskinesiaInfo
- Publication number
- SG160342A1 SG160342A1 SG201001316-7A SG2010013167A SG160342A1 SG 160342 A1 SG160342 A1 SG 160342A1 SG 2010013167 A SG2010013167 A SG 2010013167A SG 160342 A1 SG160342 A1 SG 160342A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- dyskinesia
- inhibition
- dopa
- effected
- Prior art date
Links
- 208000012661 Dyskinesia Diseases 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 abstract 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0503540A GB0503540D0 (en) | 2005-02-21 | 2005-02-21 | Inhibition or treatment of dyskinesia |
| GB0508843A GB0508843D0 (en) | 2005-04-29 | 2005-04-29 | Inhibition or treatment of dyskinesia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG160342A1 true SG160342A1 (en) | 2010-04-29 |
Family
ID=36691702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201001316-7A SG160342A1 (en) | 2005-02-21 | 2006-02-20 | Inhibition or treatment of dyskinesia |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080070952A1 (https=) |
| EP (1) | EP1850838A2 (https=) |
| JP (1) | JP2008545616A (https=) |
| CA (1) | CA2598484A1 (https=) |
| SG (1) | SG160342A1 (https=) |
| WO (1) | WO2006087577A2 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT891332E (pt) * | 1996-03-29 | 2004-07-30 | Pfizer | Derivados de 6-fenilpiridil-2-amina |
| HN1997000027A (es) * | 1996-12-06 | 1997-06-05 | Pfizer Prod Inc | Derivados de 6-fenil piridil - 2 amina |
| JP3505189B2 (ja) * | 1997-02-10 | 2004-03-08 | ファイザー・プロダクツ・インク | ２−アミノ−６−（２−置換−４−フェノキシ）−置換ピリジン |
| WO1998048826A1 (en) * | 1997-04-30 | 1998-11-05 | Northwestern University | Inhibition of nitric oxide synthase by amino acids and dipeptides |
| US6803486B2 (en) * | 2001-06-22 | 2004-10-12 | Northwestern University | Selective neuronal nitric oxide synthase inhibitors |
| US20030232739A1 (en) * | 2001-08-15 | 2003-12-18 | Pfizer Inc. | Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist |
| DOP2002000467A (es) * | 2001-10-10 | 2003-04-15 | Pfizer Prod Inc | 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas |
| US6803470B2 (en) * | 2001-10-10 | 2004-10-12 | Pfizer Inc | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines |
| CA2538339A1 (en) * | 2003-09-08 | 2005-03-24 | Northwestern University | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase |
-
2006
- 2006-02-20 CA CA002598484A patent/CA2598484A1/en not_active Abandoned
- 2006-02-20 SG SG201001316-7A patent/SG160342A1/en unknown
- 2006-02-20 JP JP2007555704A patent/JP2008545616A/ja not_active Withdrawn
- 2006-02-20 WO PCT/GB2006/000583 patent/WO2006087577A2/en not_active Ceased
- 2006-02-20 US US11/884,240 patent/US20080070952A1/en not_active Abandoned
- 2006-02-20 EP EP06709819A patent/EP1850838A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006087577A3 (en) | 2006-10-19 |
| WO2006087577A2 (en) | 2006-08-24 |
| CA2598484A1 (en) | 2006-08-24 |
| US20080070952A1 (en) | 2008-03-20 |
| JP2008545616A (ja) | 2008-12-18 |
| EP1850838A2 (en) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349787B (es) | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. | |
| SG171584A1 (en) | Nanoparticulate metal boride composition and its use for identification- marking plastic parts | |
| IL197090A (en) | A method for the identification of inhibitors of glutaminyl cyclase variants | |
| IN2012DN01869A (https=) | ||
| UA106748C2 (uk) | Похідні проліну як інгібітори катепсину | |
| IL192634A0 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
| IL192603A0 (en) | Thieno-pyridine derivatives as mek inhibitors | |
| IL196989A0 (en) | Cyclic ii-?? hydroxysteroid dehydrogenase type 1 inhibitors | |
| PL2101759T3 (pl) | Sposoby stosowania inhibitorów MEK | |
| IL194868A0 (en) | Inhibitors of the task-1 and task-3 ion channel | |
| IL195125A0 (en) | 1,3,4-oxadiazole derivatives as dgat1 inhibitors | |
| EP2195010A4 (en) | TREATMENT WITH INHIBITORS OF KALLIKREINE | |
| EP2195011A4 (en) | TREATMENT WITH CALLICINE INHIBITORS | |
| TW200745094A (en) | ATM inhibitor | |
| IL195782A0 (en) | Epoxide inhibitors of cysteine proteases | |
| ZA200807357B (en) | Inhibitors of PAI-1 for treatment of muscular conditions | |
| WO2010093787A3 (en) | Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition | |
| JO2730B1 (en) | Medications for the treatment of endometriosis | |
| IL185382A0 (en) | Multimediator dopamine transport inhibitors, and uses related thereto | |
| GB0621203D0 (en) | PLK inhibitors | |
| SG160342A1 (en) | Inhibition or treatment of dyskinesia | |
| PH12014500538A1 (en) | Methods and compositions for treating leukemia | |
| IL173706A0 (en) | Corrosion inhibitors | |
| ZA200908771B (en) | Cysteine protease inhibitors | |
| ZA200807068B (en) | Corrosion inhibitor treatment for closed loop system |